Vancomycin

Vancomycin is available as generic injectable material and as oral products including Vancocin capsules and Firvanq solution. It became a US-approved medicine in 1958 after discovery from a soil bacterium in the 1950s during the rise of penicillin-resistant staphylococci.

Early impure brown preparations were called “Mississippi mud” and caused more toxicity than modern purified formulations. Once held in reserve, vancomycin became a major hospital therapy as MRSA spread. It remains an important comparator for newer anti-MRSA drugs more than six decades after approval.

The glycopeptide binds the D-alanyl-D-alanine ends of peptidoglycan precursors, blocking the bacterial cell-wall assembly/cross-linking needed for structural integrity. This target differs from penicillin’s and retains activity against many penicillin-resistant Gram-positive organisms.

Blood-level-guided dosing balances treatment failure/resistance at inadequate exposure against nephrotoxicity at excessive exposure. In a 2006 S. aureus bloodstream-infection study, daptomycin was tested against standard therapy that included vancomycin.

FDA approval dates to 1958. IV use includes susceptible serious Gram-positive infections such as MRSA bloodstream infection, endocarditis, bone/joint infection, skin/soft-tissue infection and pneumonia. Oral vancomycin acts locally against C. difficile-associated diarrhea and staphylococcal enterocolitis; oral and IV forms are not substitutes for one another’s site of action.

IV effects include kidney injury, hearing loss, low white-cell counts, allergic reactions and the rate-related flushing/infusion reaction formerly termed “red man syndrome.” Oral effects include nausea, abdominal pain and hypokalemia.

Severe skin reactions and lasting renal or hearing damage are important concerns. High blood levels and other nephrotoxic medicines can increase risk. Exposure monitoring and formulation-specific instructions are therefore central to clinical use.